Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2013

01-01-2013 | Epidemiology

Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations

Authors: Darya Prokofyeva, Natalia Bogdanova, Natalia Dubrowinskaja, Marina Bermisheva, Zalina Takhirova, Natalia Antonenkova, Nurzhan Turmanov, Ihor Datsyuk, Shamil Gantsev, Hans Christiansen, Tjoung-Won Park-Simon, Peter Hillemanns, Elza Khusnutdinova, Thilo Dörk

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

Bloom’s syndrome is a rare autosomal recessive chromosomal instability disorder with a high incidence of various types of neoplasia, including breast cancer. Whether monoallelic BLM mutations predispose to breast cancer has been a long-standing question. A nonsense mutation, p.Q548X, has recently been associated with an increased risk for breast cancer in a Russian case–control study. In the present work, we have investigated the prevalence of this Slavic BLM founder mutation in a total of 3,188 breast cancer cases and 2,458 controls from Bashkortostan, Belarus, Ukraine, and Kazakhstan. The p.Q548X allele was most frequent in Russian patients (0.8 %) but was also prevalent in Byelorussian and Ukrainian patients (0.5 and 0.6 %, respectively), whereas it was absent in Altaic or other non-European subpopulations. In a combined analysis of our four case–control series, the p.Q548X mutation was significantly associated with breast cancer (Mantel–Haenszel OR 5.1, 95 % CI 1.2; 21.9, p = 0.03). A meta-analysis with the previous study from the St. Petersburg area corroborates the association (OR 5.7, 95 % CI 2.0; 15.9, p = 3.7 × 10−4). A meta-analysis for all published truncating mutations further supports the association of BLM with breast cancer, with an estimated two- to five-fold increase in risk (OR 3.3, 95 %CI 1.9; 5.6, p = 1.9 × 10−5). Altogether, these data indicate that BLM is not only a gene for Bloom’s syndrome but also might represent a breast cancer susceptibility gene.
Appendix
Available only for authorised users
Literature
1.
go back to reference Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345PubMedCrossRef Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345PubMedCrossRef
2.
go back to reference Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42PubMedCrossRef Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42PubMedCrossRef
3.
go back to reference Bogdanova N, Dörk T (2012) Molecular genetics of breast and ovarian cancer. Balkan J Med Genet 15(1):75–80 Bogdanova N, Dörk T (2012) Molecular genetics of breast and ovarian cancer. Balkan J Med Genet 15(1):75–80
4.
go back to reference Ellis NA, German J (1996) Molecular genetics of Bloom’s syndrome. Hum Mol Genet 5:1457–1463PubMed Ellis NA, German J (1996) Molecular genetics of Bloom’s syndrome. Hum Mol Genet 5:1457–1463PubMed
5.
go back to reference German J (1993) Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine 72:393–406PubMedCrossRef German J (1993) Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine 72:393–406PubMedCrossRef
6.
go back to reference German J, Archibald R, Bloom D (1965) Chromosomal breakage in a rare and probably genetically determined syndrome of man. Science 148:506–507PubMedCrossRef German J, Archibald R, Bloom D (1965) Chromosomal breakage in a rare and probably genetically determined syndrome of man. Science 148:506–507PubMedCrossRef
7.
go back to reference Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, Proytcheva M et al (1995) The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell 83:655–666PubMedCrossRef Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, Proytcheva M et al (1995) The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell 83:655–666PubMedCrossRef
8.
go back to reference Ababou M, Dutertre S, Lécluse Y, Onclercq R, Chatton B, Amor-Guéret M (2000) ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation. Oncogene 19:5955–5963PubMedCrossRef Ababou M, Dutertre S, Lécluse Y, Onclercq R, Chatton B, Amor-Guéret M (2000) ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation. Oncogene 19:5955–5963PubMedCrossRef
9.
go back to reference Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J (2001) Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol 153:367–380PubMedCrossRef Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J (2001) Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol 153:367–380PubMedCrossRef
10.
go back to reference Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, Peng C, Beresten S, Gueven N, Purdie D, Lees-Miller S, Ellis N, Kondo N, Lavin MF (2002) Functional link between BLM defective in Bloom’s syndrome and the ataxia-telangiectasia-mutated protein, ATM. J Biol Chem 277:30515–30523PubMedCrossRef Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, Peng C, Beresten S, Gueven N, Purdie D, Lees-Miller S, Ellis N, Kondo N, Lavin MF (2002) Functional link between BLM defective in Bloom’s syndrome and the ataxia-telangiectasia-mutated protein, ATM. J Biol Chem 277:30515–30523PubMedCrossRef
11.
go back to reference Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927–939PubMed Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927–939PubMed
12.
go back to reference Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, Wyman C, Modrich P, Kowalczykowski SC (2011) BLM–DNA2–RPA–MRN and EXO1–BLM–RPA–MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 25:350–362PubMedCrossRef Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, Wyman C, Modrich P, Kowalczykowski SC (2011) BLM–DNA2–RPA–MRN and EXO1–BLM–RPA–MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 25:350–362PubMedCrossRef
13.
go back to reference Wu L, Davies SL, Levitt NC, Hickson ID (2001) Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51. J Biol Chem 276:19375–19381PubMedCrossRef Wu L, Davies SL, Levitt NC, Hickson ID (2001) Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51. J Biol Chem 276:19375–19381PubMedCrossRef
14.
go back to reference Braybrooke JP, Li JL, Wu L, Caple F, Benson FE, Hickson ID (2003) Functional interaction between the Bloom’s syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D). J Biol Chem 278:48357–48366PubMedCrossRef Braybrooke JP, Li JL, Wu L, Caple F, Benson FE, Hickson ID (2003) Functional interaction between the Bloom’s syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D). J Biol Chem 278:48357–48366PubMedCrossRef
15.
go back to reference Ouyang KJ, Woo LL, Zhu J, Huo D, Matunis MJ, Ellis NA (2009) SUMO modification regulates BLM and RAD51 interaction at damaged replication forks. PLoS Biol 7(12):e1000252PubMedCrossRef Ouyang KJ, Woo LL, Zhu J, Huo D, Matunis MJ, Ellis NA (2009) SUMO modification regulates BLM and RAD51 interaction at damaged replication forks. PLoS Biol 7(12):e1000252PubMedCrossRef
16.
go back to reference Suhasini AN, Brosh RM Jr (2012) Fanconi anemia and Bloom’s syndrome crosstalk through FANCJ–BLM helicase interaction. Trends Genet 28:7–13PubMedCrossRef Suhasini AN, Brosh RM Jr (2012) Fanconi anemia and Bloom’s syndrome crosstalk through FANCJ–BLM helicase interaction. Trends Genet 28:7–13PubMedCrossRef
17.
go back to reference Chan KL, North PS, Hickson ID (2007) BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J 26(14):3397–3409PubMedCrossRef Chan KL, North PS, Hickson ID (2007) BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J 26(14):3397–3409PubMedCrossRef
18.
go back to reference German J, Bloom D, Passarge E, Fried K, Goodman RM, Katzenellenbogen I, Laron Z et al (1977) Bloom’s syndrome. VI. The disorder in Israel and an estimation of the gene frequency in the Ashkenazim. Am J Hum Genet 29:553–562PubMed German J, Bloom D, Passarge E, Fried K, Goodman RM, Katzenellenbogen I, Laron Z et al (1977) Bloom’s syndrome. VI. The disorder in Israel and an estimation of the gene frequency in the Ashkenazim. Am J Hum Genet 29:553–562PubMed
19.
go back to reference Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297:2013PubMedCrossRef Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297:2013PubMedCrossRef
20.
go back to reference Cleary SP, Zhang W, Di Nicola N, Aronson M, Aube J, Steinman A, Haddad R, Redston M, Gallinger S, Narod SA, Gryfe R (2003) Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 63:1769–1771PubMed Cleary SP, Zhang W, Di Nicola N, Aronson M, Aube J, Steinman A, Haddad R, Redston M, Gallinger S, Narod SA, Gryfe R (2003) Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 63:1769–1771PubMed
21.
go back to reference Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M, Turner F, Bishop DT (2005) Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 104:719–729PubMedCrossRef Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M, Turner F, Bishop DT (2005) Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 104:719–729PubMedCrossRef
22.
go back to reference Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, Suspitsin EN, Kuligina ESh, Gorodnova TV, Pfeifer W, Togo AV, Turkevich EA, Ivantsov AO, Voskresenskiy DV, Dolmatov GD, Bit-Sava EM, Matsko DE, Semiglazov VF, Fichtner I, Larionov AA, Kuznetsov SG, Antoniou AC, Imyanitov EN (2012) High prevalence and breast cancer predisposing role of the BLM c.1642 C > T (Q548X) mutation in Russia. Int J Cancer 130:2867–2873PubMedCrossRef Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, Suspitsin EN, Kuligina ESh, Gorodnova TV, Pfeifer W, Togo AV, Turkevich EA, Ivantsov AO, Voskresenskiy DV, Dolmatov GD, Bit-Sava EM, Matsko DE, Semiglazov VF, Fichtner I, Larionov AA, Kuznetsov SG, Antoniou AC, Imyanitov EN (2012) High prevalence and breast cancer predisposing role of the BLM c.1642 C > T (Q548X) mutation in Russia. Int J Cancer 130:2867–2873PubMedCrossRef
23.
go back to reference Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, Antonenkova NN, Khusnutdinova E, Lubinski J, Dörk T (2009) A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat 118:207–211PubMedCrossRef Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, Antonenkova NN, Khusnutdinova E, Lubinski J, Dörk T (2009) A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat 118:207–211PubMedCrossRef
24.
go back to reference Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T (2010) High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 78:364–372PubMedCrossRef Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T (2010) High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 78:364–372PubMedCrossRef
25.
go back to reference Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J et al (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44:312–318PubMedCrossRef Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J et al (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44:312–318PubMedCrossRef
26.
go back to reference Bogdanova N, Feshchenko S, Cybulski C, Dörk T (2007) CHEK2 mutation and hereditary breast cancer. J Clin Oncol 25(19):e26PubMedCrossRef Bogdanova N, Feshchenko S, Cybulski C, Dörk T (2007) CHEK2 mutation and hereditary breast cancer. J Clin Oncol 25(19):e26PubMedCrossRef
27.
go back to reference Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N (2005) Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Am J Hematol 78:203–206PubMedCrossRef Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N (2005) Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Am J Hematol 78:203–206PubMedCrossRef
28.
go back to reference Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H, kConFab, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Campbell IG (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 8(9):e1002894PubMedCrossRef Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H, kConFab, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Campbell IG (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 8(9):e1002894PubMedCrossRef
29.
30.
go back to reference Masmoudi A, Marrakchi S, Kamoun H, Chaaben H, Ben Salah G, Ben Salah R, Fakhfakh F, Zahaf A, Turki H (2012) Clinical and laboratory findings in 8 patients with Bloom’s syndrome. J Dermatol Case Rep 6:29–33PubMedCrossRef Masmoudi A, Marrakchi S, Kamoun H, Chaaben H, Ben Salah G, Ben Salah R, Fakhfakh F, Zahaf A, Turki H (2012) Clinical and laboratory findings in 8 patients with Bloom’s syndrome. J Dermatol Case Rep 6:29–33PubMedCrossRef
31.
go back to reference Baris HN, Kedar I, Halpern GJ, Shohat T, Magal N, Ludman MD, Shohat M (2007) Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 9:847–850PubMed Baris HN, Kedar I, Halpern GJ, Shohat T, Magal N, Ludman MD, Shohat M (2007) Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 9:847–850PubMed
32.
go back to reference Ellis NA, Offit K (2012) Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power. PLoS Genet 8(9):e1003008PubMedCrossRef Ellis NA, Offit K (2012) Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power. PLoS Genet 8(9):e1003008PubMedCrossRef
33.
go back to reference Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbański K, Mituś J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Tołoczko-Grabarek A, Medrek K, Masojć B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92:19–24PubMedCrossRef Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbański K, Mituś J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Tołoczko-Grabarek A, Medrek K, Masojć B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92:19–24PubMedCrossRef
34.
go back to reference Bogdanova N, Feshchenko S, Schürmann P, Waltes R, Wieland B, Hillemanns P, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Varon R, Dörk T (2008) Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 122:802–806PubMedCrossRef Bogdanova N, Feshchenko S, Schürmann P, Waltes R, Wieland B, Hillemanns P, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Varon R, Dörk T (2008) Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 122:802–806PubMedCrossRef
35.
go back to reference Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK (2012) Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 134:1229–1239PubMedCrossRef Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK (2012) Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 134:1229–1239PubMedCrossRef
36.
go back to reference Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 7(10):e47993PubMedCrossRef Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 7(10):e47993PubMedCrossRef
37.
go back to reference Turnbull C, Seal S, Renwick A, Warren-Perry M, Hughes D, Elliott A, Pernet D, Peock S, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Breast Cancer Susceptibility Collaboration (UK), EMBRACE, Ahmed M, Eccles D, Evans DG, Donnelly P, Easton DF, Stratton MR, Rahman N (2012) Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet 21:958–962PubMedCrossRef Turnbull C, Seal S, Renwick A, Warren-Perry M, Hughes D, Elliott A, Pernet D, Peock S, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Breast Cancer Susceptibility Collaboration (UK), EMBRACE, Ahmed M, Eccles D, Evans DG, Donnelly P, Easton DF, Stratton MR, Rahman N (2012) Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet 21:958–962PubMedCrossRef
38.
go back to reference Hoadley KA, Xue Y, Ling C, Takata M, Wang W, Keck JL (2012) Defining the molecular interface that connects the Fanconi anemia protein FANCM to the Bloom syndrome dissolvasome. Proc Natl Acad Sci USA 109:4437–4442PubMedCrossRef Hoadley KA, Xue Y, Ling C, Takata M, Wang W, Keck JL (2012) Defining the molecular interface that connects the Fanconi anemia protein FANCM to the Bloom syndrome dissolvasome. Proc Natl Acad Sci USA 109:4437–4442PubMedCrossRef
39.
go back to reference Luo G, Santoro IM, McDaniel LD, Nishijima I, Mills M, Youssoufian H, Vogel H, Schultz RA, Bradley A (2000) Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat Genet 26:424–429PubMedCrossRef Luo G, Santoro IM, McDaniel LD, Nishijima I, Mills M, Youssoufian H, Vogel H, Schultz RA, Bradley A (2000) Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat Genet 26:424–429PubMedCrossRef
Metadata
Title
Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations
Authors
Darya Prokofyeva
Natalia Bogdanova
Natalia Dubrowinskaja
Marina Bermisheva
Zalina Takhirova
Natalia Antonenkova
Nurzhan Turmanov
Ihor Datsyuk
Shamil Gantsev
Hans Christiansen
Tjoung-Won Park-Simon
Peter Hillemanns
Elza Khusnutdinova
Thilo Dörk
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2357-1

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine